Sickle Cell Disease – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Sickle Cell Disease – Drugs In Development, 2023’, provides an overview of the Sickle Cell Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Sickle Cell Disease
- The report reviews pipeline therapeutics for Sickle Cell Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sickle Cell Disease therapeutics and enlists all their major and minor projects
- The report assesses Sickle Cell Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sickle Cell Disease
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sickle Cell Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sickle Cell Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AB Science SAAddmedica SAS
Afimmune Biopharma Ltd
Agios Pharmaceuticals Inc
AkiraBio Inc
Alexion Pharmaceuticals Inc
Alfasigma SpA
Alkermes Plc
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
AntiRadical Therapeutics LLC
Ariya Bio
Ascentage Pharma Group Inc
Asklepion Pharmaceuticals LLC
Assistance Publique - Hopitaux de Paris
AstraZeneca Plc
Aviceda Therapeutics Inc
Bausch Health Companies Inc
Beam Therapeutics Inc
Bellicum Pharmaceuticals Inc
BioLineRx Ltd
bluebird bio Inc
Bristol-Myers Squibb Co
BRL Medicine Inc
Cell Source Inc
Cellectis SA
Centre for Stem Cell Research
Cetya Therapeutics Inc
CHA Biotech Co Ltd
Children's Hospital of Philadelphia
Chugai Pharmaceutical Co Ltd
CRISPR Therapeutics AG
CSL Ltd
Daiichi Sankyo Co Ltd
Duke University
Editas Medicine Inc
Emmaus Life Sciences Inc
Eterna Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fera Pharmaceuticals LLC
Fulcrum Therapeutics Inc
Function Therapeutics Inc
Functional Fluidics LLC
Gamida Cell Ltd
Garuda Therapeutics Inc
Genethon SA
GluBio Therapeutics Inc
GlycoMimetics Inc
GreenLight Biosciences Holdings PBC
GSK plc
Guangzhou Dazhou Biomedical Technology Co Ltd
Hartis Pharma SA
Hillhurst Biopharmaceuticals Inc
Homology Medicines Inc
IHP Therapeutics Inc
IllExcor Therapeutics LLC
Imago BioSciences Inc
Intas Pharmaceuticals Ltd
Invenux LLC
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
KARE Biosciences Inc
MabTics
Medeor Therapeutics Inc
Merck & Co Inc
Micelle BioPharma Inc
MimeTech Srl
Mina Therapeutics Ltd
Mind Biosciences LLC
Molecules For Health Inc
Monte Rosa Therapeutics Inc
Novartis AG
Novo Nordisk AS
NuvOx Pharma LLC
Oryzon Genomics SA
Pfizer Inc
PHD Biosciences
Phoenicia Biosciences Inc
Portage Biotech Inc
Prolong Pharmaceuticals LLC
Rare Partners Srl
Regenacy Pharmaceuticals LLC
ReNeuroGen LLC
San Rocco Therapeutics LLC
Sana Biotechnology Inc
Sanofi
Shanghai BDgene Therapeutics Co Ltd
Syros Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
TransThera Sciences (Nanjing) Inc
U.S. National Institutes of Health
University of California Los Angeles
University of California San Francisco
University of Illinois at Chicago
University of Tennessee Health Science Center
University of Texas at Dallas
Vanguard Therapeutics Inc
Vascular Vision Pharmaceuticals Co
Vertex Pharmaceuticals Inc
Vifor Pharma Management Ltd
Weill Cornell Medical College
Zr Pharma & Gmbh